BioCentury
ARTICLE | Clinical News

Thymitaq nolatrexed: Phase III data

August 8, 2005 7:00 AM UTC

In the open-label, international Phase III ETHECC trial in 446 patients, Thymitaq missed the primary endpoint of survival benefit vs. doxorubicin. Additional data were not disclosed. Thymitaq, which h...